PDCD1 and gastric cancer: More recently the Japanese Ministry of Health, Labor and Welfare (MHLW) approved nivolumab (Opdivo®, Bristol-Myers Squibb), another anti-PD-1 monoclonal IgG4 antibody, for the treatment of unresectable advanced or recurrent GC progressing after chemotherapy.